BofA raised the firm’s price target on Ascendis Pharma to $175 from $165 and keeps a Buy rating on the shares. Yorvipath Q2 EU sales were in-line with expectations and the company continues to guide to a U.S. commercial launch in Q1 of 2025 with a U.S. annual list price of $285,000, the analyst tells investors. Despite the slower near-term outlook for Skytrofa, the firm continues to be encouraged by Yorvipath’s commercial opportunity and views any weakness as an enhanced buying opportunity to the long-term Ascendis story, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Morning Movers: Nvidia dips after report of DOJ subpoena
- Ascendis Pharma price target lowered to $165 from $174 at JPMorgan
- Ascendis Pharma price target lowered to $170 from $173 at Cantor Fitzgerald
- 3 Best Stocks to Buy Now, 9/4/2024, According to Top Analysts
- Ascendis Pharma price target lowered to $264 from $277 at Wells Fargo